Trial Profile
Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ataxia telangiectasia
- Focus Adverse reactions; Registrational
- Acronyms OLE-IEDAT
- Sponsors EryDel
- 04 May 2023 This trial has been completed in Norway (Date of the global end of the trial: 2 Sep 2022).
- 19 Apr 2023 This trial has been completed in belgium(Global end date 2/9/2022), according to European Clinical Trials Database record.
- 22 Jan 2023 This trial has been completed in Poland (Global end date 2/9/2022), according to European Clinical Trials Database record.